MIR1225: A Potential Drug Target and Biomarker (G100188847)
MIR1225: A Potential Drug Target and Biomarker
MIR1225 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the MIR family of non-coding RNA-binding proteins, which are known for their ability to interact with RNA and regulate gene expression. One of the unique features of MIR1225 is its ability to form a stable complex with specific target RNAs, a process known as RNA-protein interaction. This interaction between MIR1225 and its target RNAs has led to the identification of MIR1225 as a potential drug target and biomarker.
The discovery of MIR1225 as a potential drug target and biomarker began with a study of its function in cancer. Researchers found that MIR1225 was highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, they found that MIR1225 was positively correlated with cancer cell proliferation and survival. These findings suggested that MIR1225 may be a useful biomarker for cancer diagnosis and treatment.
Another study also investigated the effects of a drug on MIR1225 expression and its role in cancer progression. The researchers found that the drug significantly reduced MIR1225 expression in cancer cells, which suggests that it may have a negative impact on cancer growth and progression. Furthermore, they found that the drug also inhibited the formation of MIR1225-protein-protein interactions, which further supports its potential as a drug target.
In addition to its potential as a cancer drug target, MIR1225 has also been identified as a potential biomarker for other diseases. For example, a study found that MIR1225 was highly expressed in the brains of individuals with Alzheimer's disease, a condition characterized by the progressive loss of brain cells. Additionally, MIR1225 was also found to be positively correlated with the level of amyloid protein in the brains of individuals with Alzheimer's disease. The identification of MIR1225 as a potential biomarker for Alzheimer's disease has implications for the development of new diagnostic tests and therapies for this debilitating condition.
Another potential application of MIR1225 is its role in the regulation of inflammation. Several studies have shown that MIR1225 is involved in the regulation of inflammation and has been implicated in the development of various inflammatory diseases. For example, a study found that MIR1225 was expressed in the inflammatory tissues of individuals with rheumatoid arthritis, a condition characterized by inflammation in the joints. Additionally, another study found that MIR1225 was involved in the regulation of inflammation and has been implicated in the development of atherosclerosis, a condition characterized by the buildup of plaque in the arteries.
In conclusion, MIR1225 is a protein that has been identified as a potential drug target and biomarker. Its interaction with specific target RNAs and its ability to form stable complexes with target RNAs make it a promising target for small molecules. Additionally, its expression is highly correlated with various diseases, including cancer, Alzheimer's disease, and inflammation. Further research is needed to fully understand the role of MIR1225 in these diseases and to develop new diagnostic tests and therapies.
Protein Name: MicroRNA 1225
The "MIR1225 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1225 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3
